Hologic, Inc. (NASDAQ:HOLX) Shares Purchased by Rhumbline Advisers

Rhumbline Advisers grew its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 5.1% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 535,348 shares of the medical equipment provider's stock after purchasing an additional 25,822 shares during the quarter. Rhumbline Advisers owned approximately 0.24% of Hologic worth $33,068,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in HOLX. Norges Bank bought a new stake in shares of Hologic in the fourth quarter valued at about $133,414,000. Boston Partners raised its holdings in shares of Hologic by 81.0% in the fourth quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider's stock valued at $257,959,000 after acquiring an additional 1,602,463 shares in the last quarter. Champlain Investment Partners LLC bought a new stake in shares of Hologic in the fourth quarter valued at about $79,291,000. Northern Trust Corp raised its holdings in shares of Hologic by 26.9% in the fourth quarter. Northern Trust Corp now owns 3,147,420 shares of the medical equipment provider's stock valued at $226,898,000 after acquiring an additional 668,086 shares in the last quarter. Finally, Invesco Ltd. raised its holdings in shares of Hologic by 16.4% in the fourth quarter. Invesco Ltd. now owns 4,070,384 shares of the medical equipment provider's stock valued at $293,434,000 after acquiring an additional 572,187 shares in the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, Director Martin D. Madaus bought 5,445 shares of the company's stock in a transaction dated Wednesday, May 7th. The shares were acquired at an average price of $55.24 per share, with a total value of $300,781.80. Following the completion of the acquisition, the director now owns 5,445 shares in the company, valued at approximately $300,781.80. This trade represents a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 1.88% of the company's stock.

Analysts Set New Price Targets

Several analysts recently weighed in on HOLX shares. Stephens decreased their price objective on Hologic from $77.00 to $70.00 and set an "overweight" rating for the company in a report on Tuesday, May 13th. Morgan Stanley dropped their price target on Hologic from $77.00 to $65.00 and set an "equal weight" rating on the stock in a research note on Monday, May 5th. Wall Street Zen lowered Hologic from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. Royal Bank of Canada lowered their price objective on Hologic from $75.00 to $70.00 and set a "sector perform" rating on the stock in a research report on Friday, May 2nd. Finally, Argus lowered Hologic from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Twelve analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Hologic has a consensus rating of "Hold" and an average target price of $77.42.

Hologic Trading Up 2.0%

NASDAQ HOLX traded up $1.26 during trading on Friday, hitting $64.33. The stock had a trading volume of 2,267,875 shares, compared to its average volume of 2,296,012. The firm has a 50 day moving average price of $58.27 and a 200 day moving average price of $65.26. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. The company has a market capitalization of $14.34 billion, a PE ratio of 20.29, a PEG ratio of 2.14 and a beta of 0.55. Hologic, Inc. has a twelve month low of $51.90 and a twelve month high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. The business had revenue of $1.01 billion during the quarter, compared to analysts' expectations of $1 billion. During the same quarter last year, the business posted $1.03 EPS. The business's quarterly revenue was down 1.2% compared to the same quarter last year. As a group, equities research analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.